Reports on the European Patent Office's (EPO) revocation of a patent giving Myriad Genetics Inc. the exclusive right to perform diagnostic tests for a breast-cancer gene. Reasons behind the decision; Claims of groups opposed to the awarding of the patent to Myriad; Other gene patents filed with the EPO.